Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2008

View Archived Issues

Privigen pharmacokinetics and high infusion rate tolerability studied

New therapeutic options for hepatitis C described in recent patent literature

Recent patents report novel therapeutic agents for neurological disorders

VIA Pharmaceuticals completes enrollment for phase II carotid endarterectomy study

Seattle Genetics begins phase I trial of SGN-33 plus Revlimid in MDS patients

Tripep presents preliminary results from the ongoing ChronVac-C study

EpiCept announces EMEA opinion on Ceplene in AML

Cell Therapeutics completes enrollment for pixantrone phase III EXTEND trial in NHL

Recent Surface Logix patent imparts new treatment option for cardiovascular disorders

Abbott and Takeda to conclude TAP joint venture

IgG-hydrolyzing enzyme shows promise against autoimmune diseases

Neoprobe reports final phase II results with Lymphoseek

Japanese registration study of Soliris completes enrollment

Novel pandemic influenza vaccine effective against H7N7 virus

New phase Ib trial evaluates NPI-2358 for NSCLC

Amrubicin receives FDA orphan drug designation for small cell lung cancer

Novel alphav integrin inhibitor profiled at Johnson & Johnson

Anesiva initiates phase III Adlea trial for postsurgical pain

Array BioPharma files IND for ARRY-614 and initiates phase I clinical trial

Anacor announces positive results from phase IIa trial of AN-2728 in psoriasis patients

DiaMedica enrolls first patient in phase II human clinical trial for DM-83

Neuropharm commences phase II NPL-2009 trial in Fragile X syndrome

Rilonacept available in U.S. for cryopyrin-associated periodic syndromes

Single dose of Iomai patch with H5N1 flu vaccine achieves protective levels

Statistical significance not shown on primary endpoint in SinuNase lavage trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...